Abstracts tagged "rheumatoid arthritis"

Abstract Number: 2220 • ACR Convergence 2025
Human Milk Fatty Acid Profiles Among Breastfeeding Mothers With and Without Systemic Autoimmune Rheumatic Diseases
Rashmi Dhital¹, Kerri Bertrand², Dilli Poudel³, Christina Chambers⁴ and Monica Guma², ¹Vanderbilt University Medical Center, Brentwood, TN, ²University of California San Diego, San Diego, CA, ³Vanderbilt University Medical Center, Nashville, TN, ⁴University of California, San Diego, La Jolla, CA
Background/Purpose: Systemic autoimmune rheumatic diseases (SARDs) such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are characterized by chronic systemic inflammation and often require…
Abstract Number: 1955 • ACR Convergence 2025
Regional variations in the relationship between pericoronary fat enhancement and atherosclerosis may reflect differences in local vascular inflammation in rheumatoid arthritis
George Karpouzas¹, Frederik Enevoldsen², Dzenan Masic², Matthew Budoff¹, Ellen-Margrethe Hauge² and Sarah Ormseth³, ¹Harbor-UCLA Medical Center, Torrance, CA, ²Aarhus University, Aarhus, Denmark, ³The Lundquist Institute for Biomedical Innovation, Torrance, CA
Background/Purpose: The composition of fat around the coronary arteries is evaluated as pericoronary adipose tissue attenuation (PCATa) on coronary CT-angiogram (CCTA). In general patients PCATa…
Abstract Number: 1886 • ACR Convergence 2025
Thirty Percent of Older Adults with Rheumatic Disease Receive High-Risk Medication
Christine Anastasiou¹, Eric Roberts², gabriela Schmajuk³ and Jinoos Yazdany⁴, ¹Stanford University, Pleasanton, CA, ²University of California, San Francisco, SF, CA, ³University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA, ⁴UCSF, San Francisco, CA
Background/Purpose: High-risk medications (HRMs) may increase the risk of adverse events such as falls and fractures, hospitalizations, hospital length of stay, and death in older…
Abstract Number: 1703 • ACR Convergence 2025
Predicting Rheumatoid Arthritis Flare Using Longitudinal Cytokine Trajectories, Machine Learning and Spatial Transcriptomic Imaging
Wittaya Suwakulsiri¹, Lukas Andriessen², Coline Fournier³, Saritha Kodikara⁴, Amy Anderson⁵, Jasmine Sim⁵, Kim-Anh Le Cao⁴, Yann Abraham⁶, Kevin Wei⁷, Kenneth Baker⁵, Arthur Pratt⁸, Mihir Wechalekar⁹, John Isaacs¹⁰ and Ranjeny Thomas¹, ¹Frazer Institute, University of Queensland, Brisbane, Queensland, Australia, ²Frazer Institute, University of Queensland, Woolloongabba, Queensland, Australia, ³Melbourne Integrative Genomics & School of Mathematics and Statistics, The University of Melbourne, Melbourne, Australia, ⁴Melbourne Integrative Genomics & School of Mathematics and Statistics, The University of Melbourne, Melbourne, Victoria, Australia, ⁵Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle, United Kingdom, ⁶DeepLife, Vernon, France, ⁷Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ⁸University of Newcastle, Newcastle, United Kingdom, ⁹Flinders Medical Centre, Adelaide, Australia, ¹⁰Newcastle University, Newcastle upon Tyne, United Kingdom
Background/Purpose: Many patients living with rheumatoid arthritis (RA) can achieve remission with modern treat-to-target disease-modifying anti-rheumatic drugs (DMARDs), albeit with the risks associated with long-term…
Abstract Number: 1648 • ACR Convergence 2025
Predicting Worse Disease Activity, QOL, and Progression to Advanced Therapies at 12 and 24 months in Early RA: Results from the Canadian Early Arthritis Cohort (CATCH)
Susan J. Bartlett¹, Marie-France Valois², Clifton Bingham³, Janet Pope⁴, Hugues Allard-Chamard⁵, Louis Bessette⁶, Gilles Boire⁷, Carol Hitchon⁸, Glen Hazlewood⁹, Bindee Kuriya¹⁰, Carter Thorne¹¹ and Vivian Bykerk¹², ¹McGill University, Beaconsfield, QC, Canada, ²McGill University, Pointe-Claire, QC, Canada, ³Johns Hopkins University, Baltimore, MD, ⁴University of Western Ontario, London, ON, Canada, ⁵Université de Sherbrooke, Sherbrooke, Canada, ⁶Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec, QC, Canada, ⁷Retired, Sherbrooke, QC, Canada, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹University of Calgary, Calgary, AB, Canada, ¹⁰University of Toronto - Toronto, Toronto, ON, Canada, ¹¹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²Hospital for Special Surgery, New York, NY
Background/Purpose: Pain, fatigue, and emotional distress are common in new RA patients. It is unclear whether co-occurring symptoms predict worse outcomes and progression to advanced therapies…
Abstract Number: 1364 • ACR Convergence 2025
Efficacy Of Ayurvedic Treatment Versus Placebo, Each In Combination With Methotrexate In Early RA Over 20 Weeks: An Exploratory Randomized Control Trial
Prativa Priyadarshani Sethi¹, Venkatesh Srinivasa Pai², Rajat Ranka², Avneet Kumar Gupta³, Ashish Baweja⁴, ritu sangwan⁵, Abhishek Rai⁶, Sryla Punjadath¹ and Nithya Maskani², ¹All India Institute of Medical Sciences, Rishikesh, Rishikesh, Uttarakhand, India, ²AIIMS RISHIKESH, Rishikesh, Uttarakhand, India, ³AIIMS RISHIKESH, Lucknow, Uttar Pradesh, India, ⁴Medanta, The Medicity, Gurugram, New Delhi, Delhi, India, ⁵AIIMS ,Rishikesh, Rishikesh, Uttarakhand, India, ⁶AIIMS ,RISHIKESH, Bhilai, Chhattisgarh, India
Background/Purpose: Early rheumatoid arthritis (RA) is a critical therapeutic window where prompt treatment targeting remission or low disease activity can significantly reduce long-term disability and…
Abstract Number: 1345 • ACR Convergence 2025
Upregulated TLR Signaling Identified in Difficult-to-Treat RA: A Propensity Score–Matched Transcriptome Study
YOSHINORI NISHIURA¹, YOSHIHARU SATO², YU NAKAI¹, MOE TOKUNAGA¹, KENTA SHIDAHARA¹ and YOSHINOBU KOYAMA³, ¹Japan Red Cross Okayama Hospital, Okayama-shi, Okayama, Japan, ²DNA Chip Research Inc., Kawasaki-shi, Kanagawa, Japan, ³Japanese Red Cross Okayama Hospital, Okayama, Okayama, Japan
Background/Purpose: Difficult-to-treat rheumatoid arthritis (D2T-RA) represents a clinically challenging RA subset defined by failure to achieve disease control despite multiple conventional and advanced therapies. The…
Abstract Number: 1329 • ACR Convergence 2025
Relationship Between Circulating Bacterial Small RNAs, Methotrexate Response, and Microbiome in New Onset Rheumatoid Arthritis
Carolina Ramirez-Becerra¹, Tulsi Joishy², Sheau-Chiann Chen², Marisol Ramirez-Solano², Quanhu Sheng², Peter Turnbaugh³, Carles Ubeda⁴, Renuka Nayak⁵, Rebecca Blank⁶, Jose Scher⁷ and Michelle Ormseth², ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University Medical Center, Nashville, ³University of California, San Francisco, San Francisco, CA, ⁴Fisabio, Madrid, ⁵University of California, San Francisco (UCSF), San Francisco, CA, ⁶NYU Langone Health, New York, NY, ⁷New York University School of Medicine, New York, NY
Background/Purpose: Microbiome and microbial products are possible contributors and predictors to methotrexate (MTX) response variability. Bacterial small RNAs (sRNAs) are found in human plasma and…
Abstract Number: 1313 • ACR Convergence 2025
Retrospective Analysis of Factors Associated With Fracture in 2855 Patients With Rheumatoid Arthritis, Stratified by Steroid Use
Jonathan Barnes¹, Hamzah Amin² and marwan Bukhari³, ¹Morecambe Bay NHS Trust, Lancaster, United Kingdom, ²Lancaster University, Lancaster, United Kingdom, ³University Hospitals of Morecambe bay NHS foundation trust, Lancaster, United Kingdom
Background/Purpose: Steroids are used in a proportion of patients with rheumatoid arthritis (RA). Steroids are known to cause a decrease in bone mineral density (BMD),…
Abstract Number: 1225 • ACR Convergence 2025
Association between Anxiety and Tender Swollen Joint Difference in Patients with Rheumatoid Arthritis
Clarice Lin¹, Burcu Aydemir², Jing Song³, Lutfiyya muhammad², Clifton Bingham⁴, Tuhina Neogi⁵, Wendy Marder⁶, Marcy Bolster⁷, Daniel Clauw⁸, Dorothy Dunlop⁹ and Yvonne Lee¹, ¹Northwestern University, Chicago, IL, ²Northwestern University Feinberg School of Medicine, Chicago, IL, ³Northwestern University Feinberg School of Medicine, Worthington, MN, ⁴Johns Hopkins University, Baltimore, MD, ⁵Boston University School of Medicine, Boston, MA, ⁶University of Michigan, Ann Arbor, MI, ⁷Massachusetts General Hospital, Concord, MA, ⁸Chronic Pain and Fatigue Research Center, University of Michigan, Ann Arbor, MI, ⁹Northwestern University Feinberg School of Medicine, Chicago
Background/Purpose: Some patients with rheumatoid arthritis (RA) have pain, despite normalization of inflammatory markers and reduced swollen joint counts. Among these patients, the number of…
Abstract Number: 1055 • ACR Convergence 2025
The Price of Relief: Examining the Role of Insurance in High-Cost Medication Use
Antara Dattagupta¹, Colin Diffie² and Sana Cheema², ¹Washington University in St. Louis, St. Louis, MO, ²Washington University in St. Louis, St. Louis
Background/Purpose: High-cost biologic therapies are integral to the management of rheumatoid arthritis (RA), yet access to these agents may be influenced by insurance type, particularly…
Abstract Number: 0996 • ACR Convergence 2025
Breaking Inflammatory Pathways: ELN28, a Novel Dual TNFα/JAK Inhibitor Drug Conjugate for Chronic Inflammation
Obinna Ubah, Euan Murray, Stella Priyanka, Julia Martinez Fraile, Andrew Porter, Robert Boyd and Caroline Barelle, Elasmogen Limited, Aberdeen, United Kingdom
Background/Purpose: Despite advances in therapies for chronic autoimmune diseases such as rheumatoid arthritis (RA), significant unmet needs persist, including therapeutic ceiling effects, adverse events, and…
Abstract Number: 0890 • ACR Convergence 2025
Granzyme K+ CD8 T cells colocalize with myeloid cells and activate them through several pathways
Julia Nicole Zeid¹, Kaitlyn Arce², Nanxi Guo¹, Kartik Bhamidipati³, Kevin Wei⁴, Larry Moreland⁵, Fan Zhang⁶ and Anna Helena Jonsson², ¹University of Colorado School of Medicine, Aurora, ²University of Colorado School of Medicine, Aurora, CO, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ⁵University of Colorado, Denver, CO, ⁶The University of Colorado, Aurora, CO
Background/Purpose: Granzyme K (GZMK)-expressing CD8 T cells have recently been detected in tissues from an increasing number of autoimmune conditions, but their role in disease…
Abstract Number: 0814 • ACR Convergence 2025
Pain Patterns in a Multicenter Randomized Trial of Early RA – Link Between Initially Sustained Joint Inflammation and Subsequent Non-inflammatory Pain Outcomes
Annie Brink¹, Johan Karlsson Wallman², Jon T Einarsson¹, Meliha Kapetanovic¹, Elisabeth Mogard¹, Elisabet Lindqvist¹, Carmen Roseman¹, Kristina Lend³, Merete Hetland⁴, Mikkel Ostergaard⁵, Kim Horslev-Petersen⁶, Dan Nordstrom⁷, Tuulikki Sokka-isler⁸, Bjorn Gudbjornsson⁹, Gerður María Gröndal⁹, Marte Heiberg¹⁰, Espen Haavardsholm¹⁰, Michael Nurmohamed¹¹, Anna Rudin¹², Ronald van Vollenhoven¹³, Till Uhlig¹⁰, Jon Lampa¹⁴ and Tor Olofsson², ¹Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden, ²Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Rheumatology, Lund, Skane Lan, Sweden, ³Department of Rheumatology and Amsterdam Rheumatology Center, Amsterdam University Medical Centers, Amsterdam; Department of Medicine, Rheumatology Unit, Center for Molecular Medicine (CMM), Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, ⁴Copenhagen Center for Arthritis Research (COPECARE) and DANBIO, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup; Department of Clinical Medicine, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark, ⁵Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, and Copenhagen Center for Arthritis Research, Center for Rheumatology, Rigshospitalet, Glostrup, Denmark, ⁶Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Sønderborg; Department of Regional Health Research, University of Southern Denmark, Odense, Denmark, ⁷Division of Rheumatology, Helsinki University Hospital, Helsinki, Finland, ⁸Department of Medicine and University of Eastern Finland, Jyväskylä Central Hospital, Juväskylä, Finland, ⁹Landspitali University Hospital; Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ¹⁰Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ¹¹Amsterdam Rheumatology and Immunology Center, Reade; Department of Rheumatology and Amsterdam Rheumatology Center, Amsterdam University Medical Centers, Amsterdam, Netherlands, ¹²Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy of University of Gothenburg, Gothenburg, Sweden, ¹³Department of Rheumatology, Amsterdam University Medical Centre, Amsterdam, Netherlands, ¹⁴Department of Medicine, Rheumatology Unit, Center for Molecular Medicine (CMM), Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Emerging data indicate an uncoupling between pain and inflammation during the RA disease course, and comorbid fibromyalgia – thought to stem from central pain…
Abstract Number: 0500 • ACR Convergence 2025
Is Methotrexate Tapering Possible In Stable RA? Clinical Observations of Methotrexate Tapering At Two Tertiary Care Centers
Sama Hajizadeh¹, Tarun Sharma¹, Peri Newman², Julio Hernandez², Rayford June³, Erik Lehman², Nicole Wilson¹, Nancy Olsen⁴ and Sharon Banks⁵, ¹Allegheny Health Network, Pittsburgh, PA, ²Penn State Health/ Penn State College of Medicine, Hershey, PA, ³Penn State College of Medicine/Lebanon VA Medical Center, Hummelstown, PA, ⁴Penn State University/Milton S Hershey, Hershey, PA, ⁵Penn State Milton S. Hershey Medical Center, Hershey, PA
Background/Purpose: In our previous Rheumatoid Arthritis Medication TAPering (RheumTAP) cohort study of patients with stable RA in remission on biologics +/- methotrexate at Allegheny Health…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].